| 5.39 0.01 (0.19%) | 01-26 11:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.11  |
1-year : | 8.3 |
| Resists | First : | 6.09 |
Second : | 7.11 |
| Pivot price | 4.92 |
|||
| Supports | First : | 4.9 |
Second : | 4.17 |
| MAs | MA(5) : | 5.09  |
MA(20) : | 5.04 |
| MA(100) : | 3.85 |
MA(250) : | 2.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 81.5 |
D(3) : | 67.4 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 7.73 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMMX ] has closed below upper band by 13.0%. Bollinger Bands are 24.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.52 - 5.55 | 5.55 - 5.57 |
| Low: | 5.01 - 5.04 | 5.04 - 5.06 |
| Close: | 5.34 - 5.38 | 5.38 - 5.42 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Mon, 12 Jan 2026
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Benzinga
Thu, 11 Dec 2025
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Tue, 09 Dec 2025
Immix Biopharma Announces Closing of Upsized $100 Million - GlobeNewswire
Tue, 09 Dec 2025
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Mon, 08 Dec 2025
Immix Biopharma, Inc. Announces Positive Phase 2 NXC-201 Results - TradingView
Sun, 07 Dec 2025
Immix Biopharma (IMMX) reports 75% CR at ASH 2025, plans 2026 NXC-201 BLA - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 22.3 (%) |
| Held by Institutions | 5.4 (%) |
| Shares Short | 2,110 (K) |
| Shares Short P.Month | 1,370 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.5 % |
| Return on Equity (ttm) | -182.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -6.93 |
| PEG Ratio | 0 |
| Price to Book value | 21.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|